Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors-Reference-Cited by-同舟云学术

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Published:2020-08-01 Issue:8 Volume:6 Page:1241
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Joensuu Heikki¹,Eriksson Mikael²,Sundby Hall Kirsten³,Reichardt Annette⁴,Hermes Barbara⁵,Schütte Jochen⁶,Cameron Silke⁷,Hohenberger Peter⁸,Jost Philipp J.⁹,Al-Batran Salah-Eddin¹⁰,Lindner Lars H.¹¹,Bauer Sebastian¹²,Wardelmann Eva¹³,Nilsson Bengt¹⁴,Kallio Raija¹⁵,Jaakkola Panu¹,Junnila Jouni¹⁶,Alvegård Thor¹⁷,Reichardt Peter⁴

Affiliation:

1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

2. Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden

3. Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

4. Helios Klinikum Berlin-Buch, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany

5. Universitätsklinikum Tübingen, Tübingen, Germany

6. Schwerpunktpraxis Oncology/Hematology, Düsseldorf, Germany

7. Department of Gastroenterology, University of Göttingen, Göttingen, Germany

8. Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, Germany

9. Medical Department III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

10. Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt, Germany

11. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany

12. Sarcoma Center, West German Cancer Center, Essen, Germany

13. Gerhard-Domagk-Institute of Pathology, University of Münster, Münster, Germany

14. Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

15. Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland

16. 4Pharma Ltd, Turku, Finland

17. Department of Cancer Epidemiology, Lund University, Lund, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2766796/jamaoncology_joensuu_2020_oi_200029_1597168363.06787.pdf

Reference15 articles.

1. Gastrointestinal stromal tumors.;von Mehren;J Clin Oncol,2018

2. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.;Dematteo;Lancet,2009

3. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.;Casali;J Clin Oncol,2015

4. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.;Joensuu;JAMA,2012

5. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.;Corless;J Clin Oncol,2014

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors;Surgical Oncology Clinics of North America;2024-01

2. Surgical management of a locally advanced jejunal stromal tumor: A case report of a challenging condition;International Journal of Surgery Case Reports;2024-01

3. Gastrointestinal stromal tumors of the rectum;coloproctology;2023-12-20

4. Recent advances for treatment of upper gastrointestinal malignancy;Journal of Surgical Oncology;2023-11-27

5. Management of locally advanced non‐small cell lung cancer: State of the art and future directions;Cancer Communications;2023-11-20